Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Ampulla of Vater
/ pathology
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Bile Ducts
/ pathology
Biliary Tract Neoplasms
/ diagnosis
Cholangiocarcinoma
/ drug therapy
Gallbladder
/ pathology
Humans
Molecular Targeted Therapy
/ methods
Mutation
Neoplasm Staging
Observational Studies as Topic
Prognosis
Progression-Free Survival
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Randomized Controlled Trials as Topic
BRAF
biliary tract cancer
cholangiocarcinoma
dabrafenib
trametinib
Journal
Cancer control : journal of the Moffitt Cancer Center
ISSN: 1526-2359
Titre abrégé: Cancer Control
Pays: United States
ID NLM: 9438457
Informations de publication
Date de publication:
Historique:
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
7
9
2021
Statut:
ppublish
Résumé
Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials. Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.
Sections du résumé
BACKGROUND
BACKGROUND
Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA).
METHODS & RESULTS
RESULTS
In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials.
CONCLUSIONS
CONCLUSIONS
Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.
Identifiants
pubmed: 33356500
doi: 10.1177/1073274820983013
pmc: PMC8642057
doi:
Substances chimiques
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073274820983013Références
Hepatology. 2019 Apr;69(4):1803-1815
pubmed: 30251463
J Clin Oncol. 2011 Jun 10;29(17):2357-63
pubmed: 21519026
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Nat Genet. 2012 May 06;44(6):690-3
pubmed: 22561520
Cancer Control. 2013 Oct;20(4):282-8
pubmed: 24077404
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Liver Int. 2019 May;39 Suppl 1:98-107
pubmed: 30831002
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
Am Soc Clin Oncol Educ Book. 2016;35:e194-203
pubmed: 27249723
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Br J Cancer. 2018 Aug;119(3):291-295
pubmed: 29955136
N Engl J Med. 2009 Jul 2;361(1):98-9
pubmed: 19571295
Clin Cancer Res. 2019 Feb 1;25(3):937-945
pubmed: 30563938
Cancer Control. 2017 Jul-Sep;24(3):1073274817729241
pubmed: 28975832
Cancer Manag Res. 2019 Mar 29;11:2623-2642
pubmed: 31015767
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441-452
pubmed: 32859625
Cancer Control. 2014 Jul;21(3):221-30
pubmed: 24955706
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460
pubmed: 28844952
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824407
Cancer Metastasis Rev. 2017 Mar;36(1):141-157
pubmed: 27981460
Hum Pathol. 2013 Dec;44(12):2768-73
pubmed: 24139215
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Br J Cancer. 2010 Aug 10;103(4):469-74
pubmed: 20628385
Crit Rev Oncol Hematol. 2020 Dec;156:103119
pubmed: 33053439
J Hepatol. 2020 Feb;72(2):353-363
pubmed: 31954497
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Gut. 2003 May;52(5):706-12
pubmed: 12692057
BMC Cancer. 2020 Apr 15;20(1):318
pubmed: 32293336
J Gastrointest Oncol. 2016 Dec;7(6):E98-E102
pubmed: 28078132
Jpn J Clin Oncol. 2018 Aug 1;48(8):703-711
pubmed: 29893894
Cancers (Basel). 2020 May 14;12(5):
pubmed: 32423017
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722188
Chin Clin Oncol. 2020 Feb;9(1):7
pubmed: 32146818
Drugs. 2020 Jun;80(9):923-929
pubmed: 32472305
Curr Treat Options Oncol. 2016 Nov;17(11):58
pubmed: 27658789
Cancer Sci. 2018 Jan;109(1):215-224
pubmed: 29121415
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
J Hematol Oncol. 2015 May 29;8:58
pubmed: 26022204
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Anticancer Res. 2020 Jun;40(6):3013-3030
pubmed: 32487595
Drugs Today (Barc). 2019 Apr;55(4):247-264
pubmed: 31050693
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
J Gastrointest Oncol. 2017 Jun;8(3):430-440
pubmed: 28736630
Curr Treat Options Oncol. 2020 Jun 29;21(8):63
pubmed: 32602010
Invest New Drugs. 2018 Dec;36(6):1037-1043
pubmed: 29785570
Cancer Discov. 2019 Aug;9(8):1064-1079
pubmed: 31109923
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
J Gastrointest Oncol. 2017 Apr;8(2):E32-E38
pubmed: 28480077
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Expert Opin Investig Drugs. 2018 Jan;27(1):17-30
pubmed: 29216787
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
JCO Precis Oncol. 2020 Jun 1;4:
pubmed: 32923885
Int J Hyperthermia. 2020;37(1):479-485
pubmed: 32396398
Br J Dermatol. 2017 Oct;177(4):893
pubmed: 29052896
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Expert Opin Investig Drugs. 2021 Apr;30(4):317-324
pubmed: 33054456
ESMO Open. 2020 Sep;5(5):e001042
pubmed: 32994319
Cancers (Basel). 2020 Aug 06;12(8):
pubmed: 32781527
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Cancer Control. 2020 Jul-Aug;27(3):1073274820948047
pubmed: 32806956